Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer
- PMID: 12014648
Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer
Abstract
Background: The role of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) enzyme activities in tumor progression and sensitivity to 5-fluorouracil (5-FU) were evaluated.
Materials and methods: TS and DPD activities were measured in 81 clinical samples of gastric cancer. TS and DPD activities were determined by 5-fluorodeoxyuridine monophosphate binding assay and by radioenzymatic assay, respectively. Sensitivity to 5-FU was determined by in vitro ATP assay.
Results: There was no correlation between TS activity and sensitivity to 5-FU. However, a weak correlation was found between DPD activity and sensitivity to 5-FU. In a subgroup of patients who did not receive adjuvant chemotherapy, overall survival was poorer in patients with high TS activity (p=0.0265). Conversely, in a subgroup of patients who received 5-FU-based adjuvant chemotherapy, overall survival was poorer in patients with high DPD activity (p=0.0465).
Conclusion: These results suggest that TS has an important role in tumor progression and DPD may be the dominant predictor of 5-FU sensitivity in gastric cancer.
Similar articles
-
Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.Oncology. 2006;70(5):366-77. doi: 10.1159/000098110. Epub 2006 Dec 15. Oncology. 2006. PMID: 17179731
-
Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer.Anticancer Res. 1999 Nov-Dec;19(6C):5635-40. Anticancer Res. 1999. PMID: 10697632
-
[Prediction of sensitivity to 5-fluorouracil (5-fu) by metabolic and target enzyme activities in colon cancer].Gan To Kagaku Ryoho. 2006 Nov;33(11):1603-9. Gan To Kagaku Ryoho. 2006. PMID: 17108726 Japanese.
-
Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.Int J Clin Oncol. 2003 Jun;8(3):132-8. doi: 10.1007/s10147-003-0330-z. Int J Clin Oncol. 2003. PMID: 12851836 Review.
-
5-fluorouracil and dihydropyrimidine dehydrogenase.Int J Clin Oncol. 2003 Jun;8(3):127-31. doi: 10.1007/s10147-003-0319-7. Int J Clin Oncol. 2003. PMID: 12851835 Review.
Cited by
-
Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives.J Clin Med. 2023 Jul 12;12(14):4646. doi: 10.3390/jcm12144646. J Clin Med. 2023. PMID: 37510761 Free PMC article. Review.
-
Relative level of thymidylate synthase mRNA expression in primary tumors and normal tissues predicts survival of patients with oral tongue squamous cell carcinoma.Eur Arch Otorhinolaryngol. 2010 Apr;267(4):581-6. doi: 10.1007/s00405-009-1062-0. Epub 2009 Aug 21. Eur Arch Otorhinolaryngol. 2010. PMID: 19697054
-
Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenase.Cancer Drug Resist. 2019 Sep 19;2(3):787-802. doi: 10.20517/cdr.2018.006. eCollection 2019. Cancer Drug Resist. 2019. PMID: 35582578 Free PMC article. Review.
-
The Sensitivity Prediction of Neoadjuvant Chemotherapy for Gastric Cancer.Front Oncol. 2021 Apr 16;11:641304. doi: 10.3389/fonc.2021.641304. eCollection 2021. Front Oncol. 2021. PMID: 33937042 Free PMC article. Review.
-
Treatment Response Predictors of Neoadjuvant Therapy for Locally Advanced Gastric Cancer: Current Status and Future Perspectives.Biomedicines. 2022 Jul 6;10(7):1614. doi: 10.3390/biomedicines10071614. Biomedicines. 2022. PMID: 35884916 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Medical